Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.
Adolescent
Age Factors
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antibodies, Neutralizing
/ therapeutic use
Antiviral Agents
/ therapeutic use
COVID-19
/ complications
Child
Consensus
Drug Combinations
Humans
Italy
Patient Selection
Risk Factors
Societies, Medical
COVID-19 Drug Treatment
Adolescents
COVID19
Monoclonal antibody
Risk factors
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
12 Jan 2022
12 Jan 2022
Historique:
received:
18
10
2021
accepted:
22
11
2021
entrez:
13
1
2022
pubmed:
14
1
2022
medline:
20
1
2022
Statut:
epublish
Résumé
The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options.The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subjects aged ≥12 with SARS-CoV-2 infection and specific risk factors.Currently the indications are specific for the use of two different mAbs combination: Bamlanivimab+Etesevimab (produced by Eli Lilly) and Casirivimab+Imdevimab (produced by Regeneron).These drugs have shown favorable effects in adult patients in the initial phase of infection, whereas to date few data are available on their use in children.AIFA criteria derived from the existing literature which reports an increased risk of severe COVID-19 in children with comorbidities. However, the studies analyzing the determinants for progression to severe disease are mainly monocentric, with limited numbers and reporting mostly generic risk categories.Thus, the Italian Society of Pediatrics invited its affiliated Scientific Societies to produce a Consensus document based on the revision of the criteria proposed by AIFA in light of the most recent literature and experts' agreement.This Consensus tries to detail which patients actually have the risk to develop severe disease, analyzing the most common comorbidities in children, in order to detail the indications for mAbs administration and to guide the clinicians in identifying eligible patients.
Identifiants
pubmed: 35022088
doi: 10.1186/s13052-021-01187-1
pii: 10.1186/s13052-021-01187-1
pmc: PMC8754075
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antiviral Agents
0
Drug Combinations
0
bamlanivimab and etesevimab drug combination
0
casirivimab and imdevimab drug combination
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Investigateurs
Francesco Blasi
(F)
Angelo Di Giorgio
(A)
Daniele Donà
(D)
Amelia Licari
(A)
Massimo Martinelli
(M)
Antonio Mastrangelo
(A)
Michele Miraglia Del Giudice
(M)
Giangiacomo Nicolini
(G)
Fabrizio Pugliese
(F)
Pasquale Striano
(P)
Giuliana Valerio
(G)
Informations de copyright
© 2022. The Author(s).
Références
Lancet Respir Med. 2021 Aug;9(8):909-923
pubmed: 33812494
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Liver Transpl. 2020 Oct;26(10):1359-1362
pubmed: 32614988
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Eur Heart J. 2021 May 14;42(19):1858-1865
pubmed: 33313664
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101610
pubmed: 33588313
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Front Med (Lausanne). 2020 Nov 13;7:572115
pubmed: 33282888
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
Pediatr Transplant. 2021 Aug;25(5):e13986
pubmed: 33689201
Lancet Haematol. 2020 Sep;7(9):e632-e634
pubmed: 32563282
Eur J Intern Med. 2011 Dec;22(6):607-10
pubmed: 22075289
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
Rheum Dis Clin North Am. 2021 Nov;47(4):797-811
pubmed: 34635305
J Cyst Fibros. 2021 Jul;20(4):566-577
pubmed: 34016559
Cardiol Young. 2021 Feb;31(2):233-240
pubmed: 33172515
J Cyst Fibros. 2020 Nov;19(6):868-871
pubmed: 33183965
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):449-451
pubmed: 33318026
JAMA Pediatr. 2021 Feb 1;175(2):176-184
pubmed: 33226415
J Am Heart Assoc. 2020 Jun 16;9(12):e017224
pubmed: 32441586
Eur J Haematol. 2020 Oct;105(4):378-386
pubmed: 32573838
Pharmaceuticals (Basel). 2021 Jul 15;14(7):
pubmed: 34358099
Ital J Pediatr. 2020 Sep 24;46(1):139
pubmed: 32972435
Gut. 2021 May;70(5):865-875
pubmed: 33753421
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Br J Haematol. 2020 Jul;190(2):e57-e58
pubmed: 32369606
Diabetes Care. 2021 Feb;44(2):526-532
pubmed: 33268335
HIV Med. 2021 Jan;22(1):e1-e2
pubmed: 32829525
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
PLoS One. 2020 Dec 10;15(12):e0243700
pubmed: 33301529
Acta Biomed. 2020 May 11;91(2):177-183
pubmed: 32420942
Am J Med Genet A. 2020 Dec;182(12):3068-3070
pubmed: 32946196
Int J Infect Dis. 2021 Feb;103:246-256
pubmed: 33227520
Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):87-100
pubmed: 33289008
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
Arch Dis Child. 2020 Dec 21;:
pubmed: 33355203
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
Lancet Respir Med. 2021 Jul;9(7):699-711
pubmed: 33676593
J Glob Health. 2020 Dec;10(2):020503
pubmed: 33110586
Br J Haematol. 2007 Oct;139(1):3-13
pubmed: 17854302
JAMA Netw Open. 2021 Jun 1;4(6):e2111182
pubmed: 34097050
J Infect. 2020 Jul;81(1):e61-e66
pubmed: 32335173
Front Pediatr. 2021 Jan 20;8:614076
pubmed: 33553073
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
J Hepatol. 2020 Sep;73(3):702-705
pubmed: 32413378
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Front Pediatr. 2021 Mar 11;9:616381
pubmed: 33777864
Pediatr Infect Dis J. 2021 Apr 1;40(4):e137-e145
pubmed: 33538539
Arch Pediatr. 2020 Jul;27(5):235-238
pubmed: 32518045
Clin Gastroenterol Hepatol. 2021 Feb;19(2):394-396.e5
pubmed: 33059040
Front Pediatr. 2021 Apr 29;9:629240
pubmed: 33996683
J Allergy Clin Immunol Pract. 2021 Feb;9(2):693-701
pubmed: 33309934
Eur J Pediatr. 2021 Oct;180(10):3237-3241
pubmed: 33768332
J Cyst Fibros. 2021 Jan;20(1):25-30
pubmed: 33309057
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
J Cell Immunol. 2021;3(2):68-77
pubmed: 33959727
Am J Respir Crit Care Med. 2021 Oct 1;204(7):857-859
pubmed: 34265234
Gut. 2021 Oct;70(10):1884-1893
pubmed: 33903149